



New York office:  
1460 Broadway  
New York  
NY 10036, USA  
Tel: +1-929-274-7510

London office:  
75-76 Wimpole Street  
London W1G 9RT, UK  
Tel: +44 (0) 20 8 0040261

To Whom It May Concern:

Akari is committed to the disclosure of results for interventional clinical trials conducted in the EEC per the requirements of Commission Guideline 2012/C 302/03. The trial listed below was registered with the EudraCT database but was cancelled/ withdrawn before it started and never enrolled any participants.

Please note that on 01-AUG-2022 this trial was prematurely ended due to the reason that Akari has taken the business decision to discontinue the clinical development programme in bullous pemphigoid (BP) and therefore the AK802 study will discontinued. The closure of the AK802 study is not related to any safety issues/concerns either within the BP or other ongoing clinical programmes.

No patient data or results will be generated from the AK802 study.

**EudraCT#** 2020-005987-67

**Study Title:** A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP)

**Sponsor Name:** Akari Therapeutics Plc